Free Trial

Cerity Partners LLC Takes Position in REGENXBIO Inc. (NASDAQ:RGNX)

REGENXBIO logo with Medical background

Cerity Partners LLC acquired a new position in shares of REGENXBIO Inc. (NASDAQ:RGNX - Free Report) during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 31,846 shares of the biotechnology company's stock, valued at approximately $228,000. Cerity Partners LLC owned 0.06% of REGENXBIO as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in RGNX. JPMorgan Chase & Co. grew its position in shares of REGENXBIO by 67.0% in the 4th quarter. JPMorgan Chase & Co. now owns 4,136,517 shares of the biotechnology company's stock valued at $31,975,000 after acquiring an additional 1,659,206 shares during the period. Janney Montgomery Scott LLC bought a new stake in shares of REGENXBIO during the 1st quarter worth about $484,000. Wealth Enhancement Advisory Services LLC bought a new stake in shares of REGENXBIO during the 1st quarter worth about $123,000. Price T Rowe Associates Inc. MD boosted its holdings in shares of REGENXBIO by 9.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 23,910 shares of the biotechnology company's stock worth $185,000 after buying an additional 1,982 shares during the period. Finally, BNP Paribas Financial Markets boosted its holdings in shares of REGENXBIO by 370.1% during the 4th quarter. BNP Paribas Financial Markets now owns 96,093 shares of the biotechnology company's stock worth $743,000 after buying an additional 75,652 shares during the period. Institutional investors own 88.08% of the company's stock.

REGENXBIO Trading Down 2.6%

RGNX traded down $0.23 during trading on Friday, reaching $8.29. 187,682 shares of the company's stock were exchanged, compared to its average volume of 990,270. REGENXBIO Inc. has a one year low of $5.03 and a one year high of $13.48. The stock has a market capitalization of $415.58 million, a PE ratio of -2.66 and a beta of 1.06. The firm has a fifty day moving average price of $8.91 and a two-hundred day moving average price of $8.00.

REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing analysts' consensus estimates of $0.41 by ($0.29). REGENXBIO had a negative net margin of 100.62% and a negative return on equity of 53.29%. The firm had revenue of $89.01 million during the quarter, compared to the consensus estimate of $105.35 million. Sell-side analysts expect that REGENXBIO Inc. will post -4.84 earnings per share for the current year.

Insider Activity

In related news, Director Kenneth T. Mills sold 20,602 shares of the business's stock in a transaction on Monday, May 12th. The shares were sold at an average price of $7.91, for a total transaction of $162,961.82. Following the transaction, the director owned 475,103 shares in the company, valued at $3,758,064.73. The trade was a 4.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 12.79% of the stock is owned by insiders.

Analysts Set New Price Targets

Several analysts recently commented on RGNX shares. Chardan Capital reaffirmed a "buy" rating and set a $52.00 target price on shares of REGENXBIO in a report on Monday, June 9th. The Goldman Sachs Group reduced their target price on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating for the company in a report on Thursday, April 17th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $31.63.

View Our Latest Stock Report on REGENXBIO

REGENXBIO Company Profile

(Free Report)

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.

Featured Articles

Institutional Ownership by Quarter for REGENXBIO (NASDAQ:RGNX)

Should You Invest $1,000 in REGENXBIO Right Now?

Before you consider REGENXBIO, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.

While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Value Plays Set to Explode
5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines